IP Library Patent Application 10981940
Patent Application
App. No. 10/981,940

Methods of monitoring glucose levels in a subject and uses thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/981,940
Abstract

Methods of frequently monitoring glucose amounts and/or concentrations in a subject who is at risk for hypoglycemia, hyperglycemia, and/or glucose level fluctuations that put the subject at risk are provided. Also provided are methods of monitoring the effects of one or more pharmaceutical compositions on the levels of glucose in a subject.

Claims (39)

1 . A method for evaluating compliance with a weight management program in a subject, said method comprising

determining a reference range of glucose amounts or concentrations that correspond to achieving a weight management goal in the subject, said range of glucose amounts or concentrations comprising a high threshold glucose value and a low threshold glucose value,

monitoring glucose amount or concentration in the subject using a glucose monitoring device that provides frequent measurement or determination of glucose amount or concentration in the subject and provides an alert or alerts when glucose levels fall outside of the reference range;

maintaining a record of caloric intake; and

comparing said series of glucose amounts or concentrations, said record, and said reference range to evaluate compliance with the reference range of glucose amounts or concentrations to achieve the weight management goal of the subject.

2 . The method of claim 1 , wherein said weight management goal is selected from the group consisting of weight gain in the subject, weight reduction in the subject, and weight maintenance in the subject.

3 . The method of claim 1 , wherein said maintaining a record further comprises recording caloric output.

4 . The method of claim 1 , wherein the glucose monitoring device maintains an on-going record of the frequent measurement or determination of glucose amount or concentration in the subject.

5 . A method for monitoring an effect of at least one non-insulin-containing pharmaceutical composition on glucose levels in a subject receiving said pharmaceutical composition, the method comprising,

monitoring glucose amount or concentration in the subject using a glucose monitoring device that provides frequent measurement or determination of glucose amount or concentration in the subject;

maintaining a record of treatment with the pharmaceutical composition; and

comparing said series of glucose amounts or concentrations and said record to evaluate the effect of the pharmaceutical composition on glucose levels in the subject receiving said pharmaceutical composition, wherein the pharmaceutical composition is not used in the subject for the treatment of diabetes.

6 . The method of claim 5 further comprising, determining a reference range of glucose amounts or concentrations that correspond to maintaining a desired range of glucose amounts or concentrations in the subject during a treatment course with said pharmaceutical composition, wherein said reference range comprises a high threshold glucose value and a low threshold glucose value.

7 . The method of claim 6 , wherein said monitoring glucose amount or concentration in the subject using the glucose monitoring device further comprises the glucose monitoring device providing an alert to the subject when a glucose amount or concentration, in the subject, at a selected time interval falls outside of the reference range.

8 . The method of claim 5 , wherein the pharmaceutical composition is pentamidine.

9 . The method of claim 5 , wherein the pharmaceutical composition is quinine.

10 . The method of claim 5 , wherein the pharmaceutical composition is saquinavir.

11 . The method of claim 5 , wherein the pharmaceutical composition is indomethacin.

12 . The method of claim 5 , wherein the subject is also receiving insulin.

13 . A method for improving prognosis and/or reduction of adverse side-effects associated with a disease state or condition in a subject, said method comprising

determining a reference range of glucose amounts or concentrations that correspond to achieving an improved prognosis or reduction of adverse side-effects associated with said disease state or condition in the subject, said range of glucose amounts or concentrations comprising a high threshold glucose value and a low threshold glucose value,

monitoring glucose amount or concentration in the subject using a glucose monitoring device that provides frequent measurement or determination of glucose amount or concentration in the subject and provides an alert or alerts when glucose levels fall outside of the reference range; and

comparing said series of glucose amounts or concentrations and said reference range to evaluate compliance with the reference range of glucose amounts or concentrations to achieve an improved prognosis or reduction of adverse side-effects associated with said disease state or condition in the subject, wherein said disease state or condition is not type I or type II diabetes.

14 . (canceled)

15 . The method of claim 13 , wherein the condition is cancer remission.

16 . The method of claim 13 , wherein the disease state is infection with human immunodeficiency virus (HIV).

17 . The method of claim 13 , wherein the disease state is infection with Candida.

18 . The method of claim 13 , wherein the condition is long distance driving.

19 . The method of claim 13 , wherein the condition is organ transplantation.

20 . The method of claim 13 , wherein the condition is growth hormone therapy.

21 . The method of claim 13 , wherein the disease state is renal failure.

22 . The method of claim 13 , wherein the disease state is infection with malaria.

23 . The method of claim 13 , wherein the condition is alcoholism.

24 . The method of claim 13 , wherein the condition is intense exercise.

25 . The method of claim 13 , wherein the disease state is cardiovascular disease.

26 . The method of claim 13 , wherein the disease state is cystic fibrosis.

27 . The method of claim 13 , wherein the disease state is stroke or ischemia.

28 . The method of claim 13 , wherein the disease state is an eating disorder.

29 . The method of claim 1 , wherein said glucose monitoring device also maintains the record of caloric intake.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2005
From: CYGNUS, INC.
To: ANIMAS TECHNOLOGIES, LLC
Reel/Frame 016210/0023 →